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Summary Brucellosis is a systemic disease and may affect many organ systems. However,
musculoskeletal involvement represents 10—85% of the focal complications. Involvement of the
spine is one of the most common localized forms of human brucellosis, especially in elderly
patients. It is a destructive disease that requires a correct and early diagnosis, and immediate
treatment. However, controversy remains over the optimal duration and antimicrobial regimen
required for the treatment of spinal brucellosis. Relapses and sequelae are still reported. In
recent years, in order to improve outcomes, alternative regimens have been investigated.
However, the classical regimen (doxycycline, 100 mg twice daily, for at least 12 weeks combined
with streptomycin, 1 g daily, for the first 2 or 3 weeks) remains the first choice of antibiotic
therapy. Alternative therapies (rifampin, fluoroquinolones, co-trimoxazole) should be considered
when adverse reactions or contraindications to the above drugs (ototoxicity, nephrotoxicity,
pregnancy, etc.) are reported.
# 2008 International Society for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.Introduction
Humanbrucellosis remainsan importantpublichealthproblem
in most developing countries, including those of the Mediter-
ranean,Balkans, theMiddleEast,Central Asia,andCentral and
South America.1,2 In developing countries, the occurrence of
the microorganism is recorded to be high because of ineffec-
tive eradication of brucellosis in animals. The high financial
cost of medical and surgical therapy considered together with
the cost of a significant morbidity in infected patients,
increases the importance of human brucellosis.3,4
Brucellosis mainly affects the musculoskeletal system,
and the spine has been reported to be the most commonly* Corresponding author. Tel.: +90 536 3146430;
fax: +90 536 3146430.
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doi:10.1016/j.ijid.2008.03.014affected site in older patients.4—8 Spinal brucellosis is defined
as involvement of the vertebral column, interspinal spaces,
and/or paraspinal areas. Despite its frequency, the diagnosis
of spinal brucellosis is usually difficult because of the late
onset of radiographic abnormalities.3,5,8 Also, the optimal
treatment regimen and duration of antibiotics remain con-
troversial, and relapses and sequelae are still important
problems.3 We describe herein the current treatment regi-
mens, and review and discuss duration of treatment with
antibiotics in spinal brucellosis.
Epidemiology and incidence
Brucellosis is a systemic disease and many organ systems
(nervous system, heart, skeletal system, bone marrow, etc.)
may become involved following hematogenous dissemina-
tion. However, osteoarticular involvement is the most com-Published by Elsevier Ltd. All rights reserved.
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has been reported in 10—85% in most series.3,9—13 The sites of
osteoarticular involvement in different studies are shown in
Table 1.9—13 Arthritis and sacroiliitis usually reflect the acute
form and frequently respond to the standard therapeutic
regimens. On the other hand, the spinal column is generally
affected in the subacute and chronic forms of brucellosis.14
Moreover, spinal brucellosis usually affects elderly patients,
whereas sacroiliitis and arthritis are usually reported in those
in the first three decades of life.5,8
The incidence of spinal brucellosis is highly variable
(2—54%) depending on the study population.10—13,15 Radio-
graphic abnormalities generally develop 3—12 weeks after
the onset of clinical symptoms.5,6,8 The spinal column can be
affected at any joint, however the lumbar spine is the most
commonly involved site, particularly the L4—L5 and L5—S1
junctions.3,8,10—13,15,16 In a review of the literature from
Turkey, we evaluated 452 spinal brucellosis cases. However,
detailed information on the anatomical location of the
lesions was available for only 305 cases. Of these lesions,
7% were cervical, 14% were thoracic, 2% were thoracolumbar,
68%were lumbar, 9%were lumbosacral, and 0.3%were sacral.
In the majority of patients (98%), a solitary lesion was
diagnosed, whereas multiple lesions were diagnosed in only
2%.6 However, the incidence of multiple site involvement has
been reported as 9—30% in the literature.3,14,17,18 Abscess
formation has rarely been reported in the past.14 However, it
has become a common finding (21—42%) following the devel-
opment of highly sensitive diagnostic techniques such as
computed tomography (CT) and magnetic resonance imaging
(MRI).12,19,20 The main causes of morbidity in spinal brucel-
losis are stated as epidural abscess, radiculoneuritis/myeli-
tis, and demyelinating neuropathy.1
Clinical features
Patient complaints in spinal brucellosis may initially be non-
specific due to the insidious nature of the disease . The most
common reported complaints are moderate fever, sweating,
malaise, back pain, and anorexia.1,3 In its acute form, the
fever may be more prominent, whereas constitutional symp-
toms (malaise, myalgia, anorexia, etc.) are common signs inTable 1 Anatomic distribution of osteoarticular involvement in
Site Aygen et al.9
n = 91
Mousa et al.10
n = 169
Sacroiliitis 53.8 20
Spondylitis 9.9 6
Knee 26.3 36
Hip — 53
Ankle 2.1 15
Elbow — 5.3
Shoulder 1 5
Wrist — 3.5
Sternoclavicular — 1.8
Foot interphalangeal 1 —
Bursitis 2.2 1.2
Polyarticular 2.1 Not stated
Acute osteomyelitis — —
Avascular necrosis — —the subacute and chronic forms.3 However, localized symp-
toms (weakness in the lower extremities (in one or both legs),
parasthesia, paraparesis, or reflex changes) may be observed
due to spinal cord or nerve root compression. Furthermore,
neurobrucellosis may develop as a complication of spinal
brucellosis, and clinical manifestations are generally menin-
gitis or meningoencephalitis.3,9 On physical examination,
general findings compatible with brucellosis (including fever,
hepatomegaly, splenomegaly) may occur together with back
pain, a positive Laseque test, and rarely signs of cauda equina
syndrome or spinal cord syndrome (e.g., sensory and motor
loss, areflexia/hyporeflexia, loss of bladder function).9,21
Diagnosis
The diagnosis of spinal brucellosis is difficult, but it is very
important for the assessment of therapy. Clinical and labora-
tory findings of brucellosis together with radiological exam-
ination of the spine are used to confirm the diagnosis of spinal
brucellosis. The earliest features are characterized by osteo-
porosis of the affected vertebral body and erosion of the
anterior—superior endplate. Narrowing of the joint space
follows this in the early form of brucellosis. The characteristic
radiographic finding of brucellosis is local erosion of the super-
ior or inferior vertebral body angle (Pons sign). Also, focal
anterior or diffuse disc collapse is frequently seen. Moreover,
due to ischemic changes and subsequent necrosis, a vacuum
phenomenonmay be observed in the anterior part of the disc.
Posterior elements are rarely involved.8,22,23 Epidural involve-
ment is also found frequently in spinal brucellosis (Figure 1).
The radiographic abnormalities of spinal brucellosis in the late
course are narrowing of the disc space, erosion, sclerosis,
vertebral collapse, and osteomyelitis.8,22,24
However, the early radiological signs of spinal brucellosis
are non-specific and the appearance of destructive changes
on direct radiographs may not be apparent until about the
third month of the disease, hence early diagnosis is not
achieved . However, the now widespread use of CT and
MRI allow the prompt diagnosis of spinal brucellosis. CT,
particularly diffusion/perfusion CT, has a high sensitivity
for early diagnosis and for the identification of the extent
of the inflammatory process.4,5,8 However, CTmay not alwaysbrucellosis — selected studies (%)
Tasova et al.11
n = 87
Colmenero
et al.12 n = 65
Pourbagher
et al.13 n = 114
60.9 45 62
13.8 58 23
8 2 —
— 3 —
5.7 6 —
— — —
— — —
— — —
— 2 —
— — —
5.7 3 11
5.7 22 —
— — 3
— — 1
Figure 1 (A) T2-weighted image showing increased signal intensity intervertebral disc space with epidural and prevertebral abscess.
(B) T1-weighted image showing irregularity and destruction of vertebral end plates with iso- to hyperintense signal intensity. (C) T1-
weighted image after contrast injection showing increased signal intensity intervertebral disc space and the inferior and superior end
plates of vertebral bodies. (D) T1-weighted axial image showing epidural and paravertebral abscess with iso- to hyperintense signal
intensity. (E) T1-weighted axial image after contrast injection showing increased signal intensity epidural and paravertebral abscess.
Current therapeutic strategy in spinal brucellosis 575be helpful in the differential diagnosis from other degenera-
tive diseases and disc herniation.15,25,26 Despite the high
sensitivity (69—91%) of bone scintigraphy, breakthroughs
have not occurred.4 MRI is the most useful method for the
diagnosis, assessment, and management of spinal brucello-
sis. Furthermore, it shows high sensitivity in the differential
diagnosis and in identifying the extent of brucellar spondy-
litis.21 The high cost of MRI limits its use in developing
countries. For this reason, the initial clinical evaluation of
the patient with other laboratory findings like C-reactive
protein (CRP) and erythrocyte sedimentation rate (ESR)
and follow-up of the patient’s symptoms and response to
therapy are very important in the consideration of spinal
involvement.
For the differential diagnosis, tuberculous spondylitis,
salmonella spondylitis, other pyogenic spondylitis, disc her-
niation, and metastatic lesions should be kept in mind.22—24
Treatment
The current World Health Organization recommended first-
line therapy for brucellosis is the combination of tetracycline
(tetracycline, 500 mg every 6 hours orally or doxycycline,
100 mg every 12 hours orally) for 6 weeks with an aminogly-
coside (preferably, streptomycin, 1 g/day intramuscularly for
2—3weeks or gentamicin 5 mg/kg/day intravenously or intra-
muscularly for 7—10 days). The combination of rifampin
(600—900 mg/day orally) and doxycycline (100 mg every
12 hours orally) for 6 weeks is suggested as the principal
alternative therapy. In spinal brucellosis, it is noted that the
same regimens can be given, but that the duration of therapy
should be for 8 weeks or more.27
The combination of doxycycline and streptomycin has
been used for a long time for complications and severe
disease.4 However, therapeutic failure and relapse are still
reported with this regimen.3,4,9,28,29 In our previous report,
the relapse rate in osteoarticular involvement was found to
be 12.1% and the highest relapse rate was in the tetracycli-
ne + streptomycin group (14.3%).9 Also, the inconvenience of
intramuscular streptomycin administration and the toxicity
of tetracycline/doxycycline and streptomycin (nausea,
vomiting, ototoxicity, nephrotoxicity, etc.) have limitedthe compliance of patients to the treatment. Other regi-
mens, such as the combination of rifampin or co-trimoxazole
with doxycycline, have been shown to be less effective than
doxcycline—streptomycin.28,29 In some studies, triple drug
regimens (doxycycline plus rifampin plus an aminoglycoside)
have been given, however there are insufficient data on the
effectiveness of triple regimens.17
As a result, other alternative regimens have been inves-
tigated in recent years. Fluoroquinolones are the most com-
monly studied antibiotics because of their good bactericidal
activity and high rates of sensitivity for Brucella spp.30—35
Furthermore, due to the ability of fluoroquinolones to pene-
trate and achieve increased concentrations in tissues and
their proven efficacy in bone and soft tissue infections, these
may lead to better outcomes in spinal brucellosis. However,
monotherapy with these antibiotics has shown high relapse
rates,36,37 though combination regimens with rifampin have
been found to be as effective as doxycycline plus rifampin in
brucellosis.33,34
In our recent study, we compared the efficacy of the
combination of ciprofloxacin (1000 mg/day, given for at least
12 weeks) and rifampin (600 mg/day, given for at least 12
weeks), with the combination of doxycycline (200 mg/day,
given for at least 12 weeks) and streptomycin (1g/day, given
for the first 3 weeks) in spinal brucellosis. Thirty-one patients
were evaluated in this study; 15 patients received a combi-
nation of doxycycline and streptomycin and 16 patients
received a combination of ciprofloxacin and rifampin. In
the ciprofloxacin—rifampin group, the patients were older,
the median ESR and CRP were higher at baseline, and abscess
formation and operation indication before therapy were
more common. In the doxycycline—streptomycin group the
rate of multifocal involvement was higher. However, the
small number of patients limited the power of the results,
and the outcome was not different in the two groups; ther-
apeutic failure was not observed in either group .21
The reported disadvantage of regimens including quino-
lones is the high cost,34,35 and in our study the cost of
ciprofloxacin—rifampin therapy was 1.2-fold higher than
the cost of doxcycline—streptomycin therapy.21 This high
cost is an important issue for developing countries. However,
the ciprofloxacin—rifampin combination could be used as an
576 E. Alp, M. Doganayalternative regimen in spinal brucellosis when adverse reac-
tions or intolerance are observed.
The duration of antibiotic therapy in spinal brucellosis is
also controversial. Relapse rates and therapeutic failures are
found to be significantly higher when antibiotics are given for
shorter periods of time.1,3,9 The duration of antibiotic ther-
apy has to be sufficient. In our previous report, the duration
of therapy was 6—8 weeks in osteoarticular involvement and
the relapse rate was 12%.9 However in our recent study, the
duration of antibiotic therapy was at least 12 weeks in spinal
brucellosis, and in some cases the therapy was prolonged
according to the resolution of clinical and MRI findings.
Relapse was not observed in any patient at the one-year
follow-up, probably due to the appropriate duration of anti-
biotic therapy.21
Diagnostic or curative surgery can be performed in spinal
brucellosis as a last option in its management. When spinal
instability, cord compression, radiculopathy, cauda equina
syndrome, and severe weakness of the muscles due to extra-
dural inflammatory mass or progressive collapse are present,
surgical intervention should be performed.12,15,21,25,35
Percutaneous drainage or aspiration of epidural and para-
vertebral abscesses can be performed instead of surgery.15
However, abscess drainage is not always necessary in the
absence of neurological deterioration and can be cured with
medical management. For the supportive management of
spinal brucellosis, analgesics and immobilization with ortho-
sis can be used to reduce the pain.15,21
Delayed convalescence after treatment is a well-known
clinical sequela in spinal brucellosis. The reason for this is not
understood, but psychoneurosis exacerbated by the infection
is suspected to be a reason for the delay. This sequela is
considered when pain, abnormal physical findings, or func-
tional limitation persist for longer than six months post-
therapy. The severity of this clinical sequela has been classi-
fied into three groups according to the patient’s functional
status: mild, moderate, and severe. The sequela is accepted
as mild if no neurological deficits remain, but pain with
exercise that does not interfere with work is present, mod-
erate if pain interferes with work or milder motor or sensorial
deficits remain, and severe if permanent and excruciating
pain (requiring rest and analgesics) or motor or sensorial
deficits remain. Mild clinical sequela can be improved with
anti-inflammatory drugs, whereas surgery can be needed in
the presence of moderate or severe sequelae.17,21
The prevention of spinal brucellosis is based on early
diagnosis and initiation of appropriate antimicrobial therapy
and the control of animal infection in endemic regions.
Conclusions
In conclusion, spinal brucellosis is still an important compli-
cation of brucellosis in endemic areas of the world. Early
diagnosis is an important issue to prevent the development of
sequelae. Highly sensitive diagnostic techniques (CTor MRA)
are the preferred techniques for early diagnosis and for the
evaluation of therapy. Patients with brucellosis should be
carefully evaluated for the localized form and spinal brucel-
losis in developing countries with limited resources. A com-
bination of doxycycline (200 mg/day, for at least 12 weeks)
with streptomycin (1 g/day, for 2 or 3 weeks) is still the first-
line antimicrobial regimen in spinal brucellosis. Doxycycli-ne + rifampin or co-trimoxazole + rifampin or ciprofloxa-
cin + rifampin or ciprofloxacin + streptomycin could be
used as an alternative when adverse reactions or contra-
indications (ototoxicity, nephrotoxicity, pregnancy, lacta-
tion, etc.) are present. The optimal duration of
antimicrobial therapy and surgical intervention when
required prevent relapse and reduce the rate of sequelae.
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